866-997-4948(US-Canada Toll Free)

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Published By :

GlobalData

Published Date : Jan 2019

Category :

Pharmaceutical

No. of Pages : 201 Pages

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Summary

Rheumatoid arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time.

In 2017, the diagnosed prevalence of RA in the 8MM averaged 0.66% in adults 18 years of age and older and 2.7% in adults aged 60 and older. Early RA typically presents as a bilateral inflammatory joint condition, usually beginning in the smaller joints such as the fingers and toes and eventually progressing to the larger joints. Patients can experience flare-ups early in the disease onset, which are typically worse in the morning. Over time, pain and swelling may become constant, ultimately leading to deformity.

Key Question Answered

With the increased entry of biosimilars into the RA marketplace, sales growth has begun to slacken and will likely continue to slow over the next 10 years.
- How will biosimilar uptake differ cross the 8MM ?
- What companies and drugs will be most affected by sales erosion from biosimilars?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are still many remaining unmet needs within the RA indication.
- What are the main unmet needs in the RA market?
- How can the pharmaceutical industry address these needs?
- To what degree will the therapies under development fulfill these unmet needs?

Although biosimilars may slow the growth of the RA market, GlobalData expects that pipeline development of agents in the JAK inhibitor class as well as other novel oral agents , will powerfully shape the RA market going forward.
- What are the main R&D trends in the RA market and which companies are leading the way?
- Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?

Scope

- Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global RA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global RA therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Rheumatoid Arthritis: Executive Summary
2.1 Biosimilar Erosion Will Temper Sales Growth in the RA Market from 2017-2027
2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies
2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA patients
2.4 Pipeline JAK1 Inhibitors Are Best Equipped to Penetrate the Crowded RA Market
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms and Severity Classifications
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
5.6 Discussion
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 Australia
7 Competitive Assessment
7.1 Overview
7.2 Biosimilars in the RA Market
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Earlier Diagnosis and Treatment
8.3 Cost-Effective Therapies
8.4 Personalized Treatment Strategies
8.5 Improved Guidance on Treating RA Patients in Remission
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Portfolio Assessments
11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 Australia
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer

1.1 List of Tables
Table 1: RA: Key Metrics in the 8MM
Table 2: RA Disease Severity Classification
Table 3: Risk Factors and Comorbidities of RA
Table 4: 1987 ACR Diagnostic Criteria for RA
Table 5: Classification Criteria for Rheumatoid Arthritis - ACR 1987
Table 6: Classification Criteria for Rheumatoid Arthritis - ACR/EULAR 2010
Table 7: Treatment Guidelines for RA throughout the 8MM, 2018
Table 8: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials
Table 9: Country Profile - US
Table 10: Regional Profile - 5EU
Table 11: Country Profile - Japan
Table 12: Country Profile - Australia
Table 13: Leading Branded Treatments for RA, 2018
Table 14: Marketed Biosimilars for RA, 2018
Table 15: Pipeline Biosimilars for RA, 2018
Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2017
Table 17: AbbVies RA Portfolio Assessment, 2018
Table 18: Pfizers RA Portfolio Assessment, 2018
Table 19: Amgens RA Portfolio Assessment, 2018
Table 20: J&Js RA Portfolio Assessment, 2018
Table 21: BMS RA Portfolio Assessment, 2018
Table 22: Roche/Genentechs RA Portfolio Assessment, 2018
Table 23: Eli Lillys RA Portfolio Assessment, 2018
Table 24: UCBs RA Portfolio Assessment, 2018
Table 25: Sanofis RA Portfolio Assessment, 2018
Table 26: Astellas RA Portfolio Assessment, 2018
Table 27: Gileads RA Portfolio Assessment, 2018
Table 28: Galapagos RA Portfolio Assessment, 2018
Table 29: R-Pharms RA Portfolio Assessment, 2018
Table 30: Taishos RA Portfolio Assessment, 2018
Table 31: Can-Fites RA Portfolio Assessment, 2018
Table 32: RA Market - Global Drivers and Barriers, 2017-2027
Table 33: Key Events Impacting Sales for RA in the US, 2017-2027
Table 34: RA Market - Drivers and Barriers in the US, 2017-2027
Table 35: Key Events Impacting Sales for RA in the 5EU, 2017-2027
Table 36: RA Market - Drivers and Barriers in the 5EU, 2017-2027
Table 37: Key Events Impacting Sales for RA in Japan, 2017-2027
Table 38: RA Market - Global Drivers and Barriers in Japan, 2017-2027
Table 39: Key Events Impacting Sales for RA in Australia, 2017-2027
Table 40: RA Market - Global Drivers and Barriers in Australia, 2017-2027
Table 41: Key Historical and Projected Launch Dates for RA
Table 42: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA
Table 43: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales Forecast by Country for RA in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period
Figure 4: Overview of RA Pathogenesis and Pathophysiology
Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs
Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages 18 Years, 2017
Figure 7: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Men, Ages 18 Years, 2007 to 2027
Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Women, Ages 18 Years, 2007 to 2027
Figure 9: 8MM, Age-Standardized Total Prevalence of RA (%), Men, Ages 18 Years, 2007 to 2027
Figure 10: 8MM, Age-Standardized Total Prevalence of RA (%), Women, Ages 18 Years, 2007 to 2027
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
Figure 12: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
Figure 13: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
Figure 14: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages 18 Years, N, 2017
Figure 17: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages 18 Years, N, 2017
Figure 20: 8MM, Diagnosed Prevalent Cases of RA By Severity, Both Sexes, Ages 18 Years, N, 2017
Figure 21: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 22: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 23: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages 18 Years, N, 2017
Figure 24: General Treatment Algorithm for RA Patients
Figure 25: Physicians Reporting Prescription of Biosimilars to at Least 25%, 50%, or 75% of Their RA Patients Throughout the 8MM, 2018
Figure 26: Physicians Reporting Prescription of Biosimilars to at Least 50% of Their RA Patients Throughout the 5EU, 2018
Figure 27: Prescription of Etanercept, Infliximab, and Rituximab Biosimilars in Comparison to Reference Biologics Among 5EU Physicians, 2017
Figure 28: Unmet Needs and Opportunities in RA, 2018
Figure 29: Overview of the Development Pipeline in RA
Figure 30: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for RA in the 8MM During the Forecast Period
Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period, 2017-2027
Figure 32: Analysis of the Company Portfolio Gap in RA During the Forecast Period
Figure 33: Global (8MM) Sales Forecast by Country for RA in 2017 and 2027
Figure 34: Global (8MM) Sales Forecast for RA, by Class, in 2017 and 2027
Figure 35: Sales Forecast by Class for RA in the US in 2017 and 2027
Figure 36: Sales Forecast by Class for RA in the 5EU in 2017 and 2027
Figure 37: Sales Forecast by Class for RA in Japan in 2017 and 2027
Figure 38: Sales Forecast by Class for RA in Australia in 2017 and 2027

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *